NOVATO, CA – December 20, 2012 - Ultragenyx Pharmaceutical Inc., a biotechnology company focused on the development of treatments for rare and ultra-rare genetic disorders, today announced the successful completion of a $75 million Series B round financing led by Adage Capital Partners, LP. Joining Adage as new investors in this financing are mutual funds and separate account clients advised by T. Rowe Price Associates, Inc., Jennison Associates LLC (on behalf of clients), funds and accounts under management by subsidiaries of BlackRock, Inc., Sanofi-Genzyme BioVentures 1, Shire plc and additional blue chip public market funds. Existing investors, TPG Biotech, Fidelity Biosciences, HealthCap and Pappas Ventures also participated in the transaction.
Ultragenyx Raises $75 Million in Oversubscribed Crossover Financing
The Wistar Institute Welcomes Three New Board Members
PHILADELPHIA—(November 16, 2012) – The Wistar Institute recently welcomed Van Billet, Joseph Goldblum and Art Pappas to its board of trustees.
Art Pappas has over 30 years of operating experience as a pharmaceutical and biotechnology industry executive and venture capital investor in life science companies. Currently, he serves as managing partner at Pappas Ventures, a life sciences venture capital firm with more than $300 million in capital under management. The firm has invested in over 50 biotechnology, biopharmaceutical, specialty pharmaceutical, drug delivery and medical device companies throughout the U.S.
Chimerix Appoints Michelle Berrey Chief Medical Officer
RESEARCH TRIANGLE PARK, NC, November 12, 2012 — Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that Michelle Berrey, MD, MPH, has joined the company as Chief Medical Officer.
"We are delighted to have Michelle join our leadership team. Dr. Berrey is a seasoned drug developer who has established a strong track record in antivirals, in particular with nucleotide analogs. She joins Chimerix at an important time for the company as our lead compound, CMX001, advances into Phase 3 clinical testing,” said Kenneth I. Moch, Chimerix President and Chief Executive Officer. “Her extensive background in antiviral drug development will be invaluable to our already strong team.”
TYRX(R) Receives Health Canada Approval
MONMOUTH JUNCTION, N.J., Oct 04, 2012 (BUSINESS WIRE) -- TYRX, Inc., the leader in the commercialization of implantable medical devices intended to help reduce surgical site infections, announced today that it has received a license from Health Canada to market its AIGISRx Antibacterial Envelope. The AIGISRx Envelope is specifically designed to stabilize pacemakers and implantable defibrillators while also releasing antimicrobial agents to help provide protection from microbial colonization of the device during surgical implantation.
FierceMedicalDevices Names TYRX® as one of its “Fierce 15” Medical Device and Diagnostic Companies of 2012
Monmouth Junction, NJ – (October 2, 2012) – TYRX, Inc. announced today that it has been named to the FierceMedicalDevices “Fierce 15” list, designating it as one of the leading medical device and diagnostic companies of 2012.
FierceMedicalDevices Editors Mark Hollmer and Damian Garde, in conjunction with Editor-in-Chief John Carroll and Executive Editor Ryan McBride, chose this year's winners based on their top management teams, notable financial backing, and promising technologies and market opportunities. TYRX was chosen as one of the Fierce 15 based, in part, on its creativity and innovations in the industry.
CardioDx Honored as One of FierceMedicalDevices’ Fierce 15 Most Promising Private Companies
PALO ALTO, Calif. – Oct. 2, 2012 – CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced that the company has been named one of FierceMedicalDevices’ Fierce 15 most promising privately held medical device and diagnostics companies in the world. FierceMedicalDevices editors chose this year's winners based on their top management teams, notable financial backing, promising technologies and market opportunities. The award was presented today at an event that took place during AdvaMed 2012: The MedTech Conference in Boston, Mass.
Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
NOVATO, Calif., May 1, 2012 /PRNewswire/ Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced results from a first-in-human, multi-center, Phase 1 study of UX001 in patients with hereditary inclusion body myopathy (HIBM) showing that UX001 was well-tolerated with an expected extended release profile on absorption after oral administration. UX001 is an extended release formulation of sialic acid intended as a substrate replacement therapy for HIBM, a severe, neuromuscular disease caused by sialic acid deficiency. Based on the Phase 1 results, Ultragenyx plans to initiate an international, multi-center, randomized, double-blind, placebo-controlled, parallel group Phase 2 study of UX001 in HIBM patients in the second quarter of this year.
LipoScience Receives 2012 Diagnostic Marketing Association Creative Communications First Place Award
NMR LipoProfile® test campaign communicates importance of LDL-particles in cardiovascular disease risk and management
RALEIGH, N.C.- April 26, 2012 (BUSINESS WIRE) -- LipoScience, Inc., an in vitro diagnostic company advancing patient care by developing high value proprietary clinical diagnostic tests using nuclear magnetic resonance (NMR) technology, today announced that it has received first place recognition at the 2012 Diagnostic Marketing Association (DxMA) Creative Communications Awards for the integrated print and online category for LipoScience’s NMR LipoProfile® test campaign.
The award was presented at the 2012 DxMA awards reception on April 25 in Chicago. The DxMA recognizes excellence in diagnostics marketing, advertising and promotional programming. LipoScience partnered with Motivation Mechanics, a Philadelphia-based marketing research and communications strategy firm, on the campaign.
Ultragenyx Announces the Completion of the Phase 1 Clinical Study of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
NOVATO, Calif., March 8, 2012 /PRNewswire/ -- Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the Phase 1 study of UX001 for hereditary inclusion body myopathy (HIBM) has been completed. UX001 is an extended release formulation of sialic acid intended as a substrate replacement therapy for HIBM, a severe, neuromuscular disease caused by sialic acid deficiency. UX001 is the first program from the company's pipeline to enter the clinic since its founding in 2010. The FDA Office of Orphan Products Development has granted orphan drug designation for UX001 for the treatment of HIBM.
BrainCells Inc. Announces the Successful Completion of the Single Ascending Dose Study With BCI-838 and the Initiation of the Multiple Ascending Dose Study
SAN DIEGO, Feb. 29, 2012 /PRNewswire/ -- BrainCells Inc., a leading biotechnology company developing novel compounds for the treatment of central nervous system (CNS) diseases, announced today that the Phase 1 single ascending dose (SAD) study of BCI-838 has been successfully completed and that the company has initiated the Phase 1 multiple ascending dose (MAD) study. The SAD study evaluated BCI-838 for safety, tolerability, pharmacokinetics and food effect in healthy male subjects. Single oral doses of BCI-838 up to 900 mg were administered and the drug was well tolerated. No serious adverse events were reported and all adverse events were mild in intensity, transient, and resolved without sequelae.
